Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer

We retrospectively evaluated if personalized Kampo medicine (PKM) could facilitate CTL responses and clinical benefits induced by personalized peptide vaccination (PPV), in which HLA-matched vaccines were selected and administered based on the preexisting host immunity, for advanced esophageal cance...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2016-01, Vol.2016 (2016), p.1-12
Main Authors: Itoh, Kyogo, Yamaguchi, Rin, Okuda, K., Naito, Masayasu, Sakamoto, Shinjiro, Yamada, Akira, Shichijo, Shigeki, Yutani, Shigeru, Muroya, Daisuke, Morita, Michi
Format: Article
Language:English
Subjects:
Anemia
Antigens
Biomarkers
Cancer
Cancer therapies
Chemotherapy
Cytokines
Cytotoxicity
Development and progression
Esophageal cancer
Lymphocytes
Medical research
Medicine
Medicine, Botanic
Medicine, Experimental
Medicine, Herbal
Neutrophils
Pay-per-view television
Peptides
Pharmaceutical industry
Studies
T cells
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We retrospectively evaluated if personalized Kampo medicine (PKM) could facilitate CTL responses and clinical benefits induced by personalized peptide vaccination (PPV), in which HLA-matched vaccines were selected and administered based on the preexisting host immunity, for advanced esophageal cancer (aEC) patients. Among 34 aEC patients entered in the clinical study, 23 patients received PKM and PPV without ( n = 12 ) or with chemotherapy ( n = 11 ), while the remaining 11 patients did not receive PKM but received PPV without ( n = 6 ) or with chemotherapy ( n = 5 ), respectively. Incidence of adverse events was significantly lower or higher in PKM and PPV arm ( n = 23 ) or PPV and chemotherapy arm ( n = 16 ) as compared to that of the counter arm ( n = 11 or 18), respectively. Postvaccination PBMCs from the patients undergoing PKM and PPV showed significantly higher CTL responses as compared to the counter arm. The median progression-free survival (PFS) or median survival time (MST) of 34 patients was 2.9 or 7.6 months, respectively. The combination therapy in PPV and PKM arm, but not that in PPV and chemotherapy arm, significantly ( P = 0.02 ) prolonged MST. These results could warrant a next step of prospective clinical study of PKM and PPV for aEC patients.
ISSN:1741-427X
1741-4288
DOI:10.1155/2016/5929525